-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Initiates Coverage On PTC Therapeutics with Buy Rating, Announces Price Target of $80

Benzinga·06/17/2025 14:28:12
Listen to the news
Truist Securities analyst Joon Lee initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Buy rating and announces Price Target of $80.